Analysts Set Henry Schein, Inc. (NASDAQ:HSIC) Target Price at $87.64

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have earned an average recommendation of “Hold” from the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $87.6429.

Several research firms recently commented on HSIC. BTIG Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Thursday, June 11th. Wall Street Zen cut shares of Henry Schein from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Mizuho reduced their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Morgan Stanley restated an “underweight” rating and set a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a report on Monday, May 4th.

Henry Schein Price Performance

Henry Schein stock opened at $87.82 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $10.00 billion, a PE ratio of 26.53, a price-to-earnings-growth ratio of 1.69 and a beta of 0.81. Henry Schein has a 12-month low of $61.94 and a 12-month high of $89.34. The firm has a 50-day moving average price of $79.50 and a 200-day moving average price of $77.72.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The company had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. Henry Schein’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts forecast that Henry Schein will post 5.32 EPS for the current year.

Insiders Place Their Bets

In other news, Director William K. Daniel bought 10,000 shares of Henry Schein stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $69.19 per share, with a total value of $691,900.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 0.89% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein during the 2nd quarter valued at $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter valued at $27,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Henry Schein during the fourth quarter valued at $30,000. Federated Hermes Inc. purchased a new stake in Henry Schein during the 4th quarter worth about $32,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Henry Schein during the 4th quarter worth about $37,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.